Abstract:Background: The global burden of non-alcoholic fatty liver disease (NAFLD) is growing, but its subsequent health consequences have not been thoroughly examined. We performed phenome-wide Mendelian randomization and disease-trajectory analyses to comprehensively assess the health outcomes of NAFLD.Methods: PheWAS analyses were conducted to map the associations of NAFLD with a broad range of phenotypes among 475,554 European in UK Biobank. Disease-trajectory and comorbidity analyses were applied to visualize the sequential patterns of multiple comorbidities related to the occurrence of NAFLD. The associations jointly verified by observational and polygenic PheWAS analyses were further replicated by two-sample MR analysis using data from the FinnGen study and international consortia.Findings: PheWAS analyses including 1,172 disease outcomes revealed the associations of NAFLD diagnosis (n=9,035) with intrahepatic (e.g., cirrhosis, liver abscess and liver cancer) and extrahepatic diseases, including circulatory diseases (i.e., various cardiac diseases, hypertension and cerebrovascular diseases), metabolic diseases (i.e., hyperlipidemia and diabetes mellitus), genitourinary system diseases (i.e., renal failure), neurological disorders (i.e., dementias and Alzheimer's disease), gastrointestinal diseases (i.e., gastritis, duodenitis and ulcerative colitis, stomach cancer and other malignant digestive neoplasms) and hematologic diseases (i.e., iron deficiency anemia and thrombocytopenia). Disease-trajectory and comorbidity network analyses identified 3 major extrahepatic comorbidities clusters related to NAFLD, mainly in cardiovascular, metabolic, and inflammatory diseases. Two-sample MR analyses supported the causal associations between NAFLD and the risk of several intrahepatic disorders, metabolic diseases, cardio-cerebro-vascular disease and ascites, but found no associations with neurological diseases (i.e., dementia).Interpretation: A prior diagnosis of NAFLD was associated with an increased risk of various extrahepatic diseases of circulatory, metabolic, genitourinary, gastrointestinal and possibly neurological systems. Three major sequential patterns of comorbidities related to NAFLD were identified, mainly in cardiovascular, metabolic and inflammatory diseases, contributing to development of combination interventions targeting distinct pathways for the health promotion among NAFLD patients.Funding: XL: the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001) and the National Nature Science Foundation of China (N0. 82204019); SCL: the Swedish Heart-Lung Foundation (Hjärt-Lungfonden, 20210351), the Swedish Research Council (Vetenskapsrådet, 2019-00977), and the Swedish Cancer Society (Cancerfonden).Declaration of Interest: All authors report no potential conflicts of interest.Ethical Approval: Ethical approval was granted by the UK Biobank by the North West-Haydock Research Ethics Committee (REC reference: 16/NW/0274).

Single nucleus RNA-sequencing integrated into risk variant colocalization discovers 17 cell-type-specific abdominal obesity genes for metabolic dysfunction-associated steatotic liver disease

Identification of genes conferring individual-level variation responsible for metabolic dysfunction-associated steatohepatitis using single-cell eQTL analysis

Integration of single cell omics with biobank data discovers trans effects of SREBF1 abdominal obesity risk variants on adipocyte expression of more than 100 genes

Potential causal links between genetic variants in SAMM50, SUGP1, MAU2, and GATAD2A and liver fat in individuals with normal weight

A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes

Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease

Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease

348-OR: Multiancestry Whole Genome Sequencing (WGS) Meta-analysis to Identify Loci Associated with Imaging-Measured Hepatic Steatosis

Multisystem Health Comorbidity Networks of Nonalcoholic Fatty Liver Disease: Phenome-Wide Mendelian Randomization and Disease-Trajectory Analyses

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Machine learning across multiple imaging and biomarker modalities in the UK Biobank improves genetic discovery for liver fat accumulation

Identification of Rare Loss-of-Function Genetic Variation Regulating Body Fat Distribution

Identification of TBX15 as an adipose master trans regulator of abdominal obesity genes

Integrating Genetic and Transcriptomic Data to Identify Genes Underlying Obesity Risk Loci

Hepatic and adipose tissue transcriptome analysis highlights a commonly deregulated autophagic pathway in severe MASLD

Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

Genome-wide association study of abdominal MRI-measured visceral fat: The multiethnic cohort adiposity phenotype study

Combining evidence from human genetic and functional screens to identify pathways altering obesity and fat distribution

WHOLE GENOME SEQUENCING ANALYSIS OF BODY MASS INDEX IDENTIFIES NOVEL AFRICAN ANCESTRY-SPECIFIC RISK ALLELE

A non-coding variant linked to metabolic obesity with normal weight affects actin remodelling in subcutaneous adipocytes